Evidence map›Paper›PMID 35468127›Full record

ArticlePLoS computational biology2022

Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection.

Ryuichi Kumata, Shoya Iwanami, Katrina B Mar, Yusuke Kakizoe, Naoko Misawa, Shinji Nakaoka, Yoshio Koyanagi, Alan S Perelson, John W Schoggins, Shingo Iwami and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS computational biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Ryuichi KumataDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-6428-6357
Shoya Iwanamiinterdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID 0000-0003-1474-5348
Katrina B MarDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.ORCID 0000-0003-3640-2418
Yusuke KakizoeMathematical Biology Laboratory, Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan.
Naoko MisawaLaboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0001-9362-803X
Shinji NakaokaLaboratory of Mathematical Biology, Faculty of Advanced Life Science, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-3277-9552
Yoshio KoyanagiLaboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.ORCID 0000-0002-3007-6642
Alan S PerelsonTheoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.ORCID 0000-0002-2455-0002
John W SchogginsDepartment of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.ORCID 0000-0002-7944-6800
Shingo Iwamiinterdisciplinary Biology Laboratory (iBLab), Division of Biological Science, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID 0000-0002-1780-350X
Kei SatoDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4431-1380
Kyoto University · JPThe University of Texas Southwestern Medical Center · USHokkaido University · JPKyushu University · JPLos Alamos National Laboratory · USNagoya University · JP

Funding

INTEGRATIVE IMMUNOLOGY TRAINING PROGRAMT32AI005284 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Nan Yan · 2003 to 2026
$7.4M
Modeling Viral and T Lymphocyte DynamicsR01OD011095 · OD · TRIAD NATIONAL SECURITY, LLC · PI PERELSON, ALAN S · 2012 to 2024
$5.0M
Immune System Modeling/HIVR01AI028433 · NIAID · UNIVERSITY OF CALIF-LOS ALAMOS NAT LAB · PI PERELSON, ALAN S · 1990 to 2021
$3.7M
Discovery of antiviral mechanisms in batsDP2AI117922 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI SCHOGGINS, JOHN W. · 2014 to 2016
$2.6M
NIAID NIH HHS DP2 AI117922NIAID NIH HHS R01 AI028433NIAID NIH HHS T32 AI005284NIH HHS R01 OD011095
6 · The paper itself

Abstract

In HIV-1-infected individuals, transmitted/founder (TF) virus contributes to establish new infection and expands during the acute phase of infection, while chronic control (CC) virus emerges during the chronic phase of infection. TF viruses are more resistant to interferon-alpha (IFN-α)-mediated antiviral effects than CC virus, however, its virological relevance in infected individuals remains unclear. Here we perform an experimental-mathematical investigation and reveal that IFN-α strongly inhibits cell-to-cell infection by CC virus but only weakly affects that by TF virus. Surprisingly, IFN-α enhances cell-free infection of HIV-1, particularly that of CC virus, in a virus-cell density-dependent manner. We further demonstrate that LY6E, an IFN-stimulated gene, can contribute to the density-dependent enhancement of cell-free HIV-1 infection. Altogether, our findings suggest that the major difference between TF and CC viruses can be explained by their resistance to IFN-α-mediated inhibition of cell-to-cell infection and their sensitivity to IFN-α-mediated enhancement of cell-free infection.

Indexed as

HIV-1HIV InfectionsAntiviral AgentsHumansInterferon-alphaAntiviral AgentsInterferon-alpha

Identifiers

PMID35468127
PMCPMC9037950
OpenAlexW4224867183

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.